Main container

Toracchio Lisa, MSc


Date of Birth


Current assignment

PhD Student

Title of qualification awarded

2014:Bachelor’s Degree in Biotechnology  University of L’Aquila, final mark: 109/110

Other qualifications awarded

2017: Master Degree in Molecular and Industrial Biotechnology at the University of Bologna, 110/110 cum Laude

Positions held
  • 2023-present: Researcher in Health at Laboratorio di Oncologia Sperimentale 
  • 2020-present: PhD Student (Oncology, Hematology and Pathology Unibo) at Experimental Oncology Lab of Rizzoli Institute, Bologna.
  • May 2020-April 2023: Fellowship at Experimental Oncology Lab of Rizzoli Institute, Bologna.
  • May 2018 – Septrember 2019: Technician at Janssen-Pharmaceutical Companies of Jhonson & Jhonson (Latina)
  • August 2017- May 2018: Pharmaceutical and validation consultant at SGS sertec Srl (Bologna).

Italian: mother tongue
English: B2

  • HPLC and UPLC, Dissolution test, Karl Fischer, NIR, IR, TLC, UV
  • Data analysis programs: Empower, Nugenesis, Lims
  • IT tool: Excel, Word, Power Point, Open Office, SPSS, Latex, SAP
  • Molecular Biology techniques: RNA extraction and quantification; PCR; Real Time PCR; protein extraction; Western Blotting; RNA immunoprecipitation assay
  • Cell culture techniques: manage of human tumoral cells; transfection techniques; soft-Agar; Motility Test; Homotipic aggregation; Wound healing assay
  • Immunohistochemistry; Immunofluorescence on fixed and non fixed cells, citofluorimetric analisys (FACS).
Teaching activities

Accelerating Biomarkers and targeted therapy development in metastatic Ewing Sarcomas: Focus on cell plasticity.

Scientific activities
  • “CIC-Rearranged Sarcomas: An Intriguing Entity That May Lead the Way to the Comprehension of More Common Cancers”. Cancers (Basel). 2022 Link:
  • “Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma”, Cancer Research, 2022 Link:
  • “Insulin like growth factor 2 mRNA-binding protein 3 influences sebsitivity to anti-IGF system agents through the translationalregulation of IGF1R”, Frontiers in Endocrinology, section Cancer Endocrinology,2018 Link:
  • “Insulin like growth factor 2 mRNA-binding protein 3 is a novel post-transcriptional regulator of Ewing Sarcoma Malignancy”, Clinical Cancer Research,2018 Link:
Clinical and/or Scientific interests

Oncologic Research, Ewing sarcoma, Osteosarcoma, IGF2BP3, BET inhibitor.